Clinical Trials
13 trialsNCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT06275854 2025-10-14
YASU Research Registry: For Young Adults With Cancer
Young Adult Survivors United
Terminated
NCT04144140 2024-03-07
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
Phase 1 Terminated
NCT04609579 2024-01-30
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
Phase 1 Terminated
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT03849950 2021-09-30
Self-Management and Activation to Reduce Treatment-Related Toxicities (SMARTCare)
University Health Network, Toronto
Phase NA Terminated
NCT01557881 2020-02-24
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Case Comprehensive Cancer Center
Phase NA Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT02062632 2019-10-01
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
Phase 2 Terminated
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01829971 2016-09-27
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
Phase 1 Terminated
NCT02080416 2016-06-10
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated